CELGENE CORPORATION

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

VerImmune Inc. secures $4.5 million in Pre-Series A funding led by Beiley Biofund. The company plans to advance its ViP-based therapeutics, including the lead product VERI-101, a cancer immunotherapy. New board members Dr. Che Hsu and Dr. Marta New bring extensive experience in novel modalities.

VerImmune Inc. secures $4.5 million in Pre-Series A financing, led by Beiley Biofund, to advance its Virus-inspired Particle (ViP™) platform technology. The funding will support the development of VERI-101, a first-in-class cancer immunotherapy, and expand strategic partnerships. The company also adds Dr. Che Hsu and Dr. Marta New to its Board of Directors.

PD-1 inhibition with pembrolizumab before and after surgery significantly improves 5-year overall survival (86.6% vs 81.7%) in high-risk early triple-negative breast cancer, according to KEYNOTE-522 trial results.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Tomas Babak's Leapfrog Bio aims to improve cancer drug success rates by screening Phase II-failed drugs on genetically engineered cells with known oncogenic mutations, using a Precision PGx Platform to identify safe, responsive drugs for specific genotypes.

The Orphan Drugs Market is projected to grow from USD 225.9 Billion in 2023 to USD 493.21 Billion by 2031, driven by rising prevalence of rare diseases, unmet medical needs, favorable regulatory policies, technological advancements, and growing public and patient advocacy. Key challenges include high R&D costs, limited patient populations, pricing and reimbursement issues, and lack of long-term data. Trends include focus on gene therapies, personalized medicine, stakeholder collaboration, and expansion into emerging markets. North America leads the market, followed by Europe and Asia Pacific.

The Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028 report highlights the emergence of CD47 inhibition as a novel cancer immunotherapy, with multiple candidates in clinical trials, including magrolimab and evorpacept. The market is rapidly evolving, driven by rising cancer incidence and increased use of immunotherapies, with significant commercial interest and notable acquisitions. Challenges include managing toxicity and demonstrating therapeutic advantages over current treatments.